CPSA USA 2019

Clinical and Pharmaceutical Analysts United:
Human Wellbeing is Our Responsibility

Executive Roundtable Archive

Where Technology and Business Meet!

2019 Executive Roundtable

Women in Science and Technology

Discussion Leaders: Lucinda R. Hittle, Merck; Emily Ehrenfeld, New Objective

Go to Program

2018 Executive Roundtable

Big Ideas, Big Data: Where Do We Go From Here?

Discussion Leaders: Lucinda R. Hittle, Merck; Emily Ehrenfeld, New Objective

Discussion Panel:
Donald Chace, Medolac Laboratories
Binodh DeSilva, Bristol-Myers Squibb
Joanna Pols, Regeneron
Robyn Rourick, Genentech
Roy Vaz, Sanofi
Eric Yang, GlaxoSmithKline
Yi Zhang, SCIEX

Go to Program

2017 Executive Roundtable

Discussion Leaders: Lucinda R. Hittle, Merck; Emily Ehrenfeld, New Objective

Discussion Panel:
Donald Chace, Medolac Laboratories
Binodh DeSilva, Bristol-Myers Squibb
Joanna Pols, Regeneron
Robyn Rourick, Genentech
Roy Vaz, Sanofi
Eric Yang, GlaxoSmithKline
Yi Zhang, SCIEX

Go to Program

2016 Executive Roundtable

Discussion Leaders: Lucinda R. Hittle, Merck; Emily Ehrenfeld, New Objective

Discussion Panel:
Donald Chace, Medolac Laboratories
Joanna Pols, Regeneron
Robyn Rourick, Genentech
Roy Vaz, Sanofi
Eric Yang, GlaxoSmithKline
Yi Zhang, SCIEX

Go to Program

2015 Executive Roundtable

Discussion Leaders: Lucinda Cohen, Merck; Shane Needham, Alturas Analytics

Go to Program

2014 Executive Roundtable

Expanding Pharmaceutical and Biochemical Diagnostics for Personalized Health Management

Discussion Leader: Timothy Olah, Bristol-Myers Squibb

As traditionally established practices to treat disease continue to bend under the weight of bureaucracy and legal liability, substandard yet excessively conservative care at unrealistically high cost, aggressively competitive pricing, and shrinking short-term profit margins, alternative commercial strategies to self-maintain health and personalize medical treatments are beginning to emerge. Access to unfiltered information through the cloud, has educated consumers through testimonials, expert opinions, experimental data, and provide risk-benefit options to be explored and evaluated. The possibility of self-administered or walk-in non-invasive sampling coupled with exceptional technological advances in diagnostics coupled with rapid electronic modeling, interpretation, and reporting exists today. How far will it go as the transformation to personalized medicine progresses?

Topics: Establishing markets to commercialize, regulations and legal liability, patient rights and accountability Patient PK, Pain Management, Medicinal Cannibas, Health Fitness Centers

Go to Program

2013 Assessing the Effect of Medicinal Marijuana on Patient Care and Businesses Comprising (and on the Periphery of) the Pharmaceutical Industry

Discussion Leader: Timothy Olah, Bristol-Myers Squibb

As of today, at least 20 states have approved the use medicinal marijuana as part of the treatment for ALS, MS, AIDS, cancer, epilepsy, and other afflictions. These approvals are the result of a growing number of patients and advocates demanding a legal and safer means to gain access to this "drug." It is estimated that over 500,000 patients in New Jersey may be eligible to obtain medicinal marijuana. Since all of these patients are also being aggressively treated with traditional drugs, what are the implications of adding medicinal marijuana to their disease management? What types of studies need to be conducted (and by whom) to determine the benefits and/or liabilities of prescribing medicinal marijuana to patients? What are legal restrictions and regulatory guidelines overseeing this burgeoning industry and how will they be enforced and governed? This session will discuss the effect that medicinal marijuana is beginning to have on health care providers and businesses associated with the pharmaceutical industry.

Discussion Panel:
Ken Lewis, OpAns
Joanna Pols, Merck
Bill Thomas, Compassionate Care Foundation

Go to Program

2012 Cost-Disciplined Science

Discussion Leader: Timothy Olah, Bristol-Myers Squibb

The concept of conducting "cost-disciplined science" has forever altered the traditional research landscape and created an increasingly competitive business environment. "Change" has always been a catalyst for "Innovation", but has the amplified focus on the "bottom line" adversely affected our ability to advance and implement technical solutions optimally? Where do Technologies and Solutions now meet Businesses and is this new interface/alignment sustainable for long term growth? Do the technologies and solutions to our challenges exist today, but are unavailable to scientists who need them because of business attitudes? The Executive Roundtable will examine these emerging issues and feature open discussions from industry leaders who will share their perspectives.

Go to Program